Diazepam
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Diazepam: From Anxiety and Seizure Disorders to Insomnia
One-Sentence Summary
Diazepam is a long-established benzodiazepine, classically used for anxiety, seizure disorders, muscle spasm and alcohol withdrawal (the formal original-indication and MOA fields are not populated in this dataset). The TxGNN model predicts it may also be effective for Insomnia, with 24 clinical trials and 18 publications currently retrieved for this pairing — though, as detailed below, most of this evidence concerns benzodiazepine discontinuation rather than new efficacy for insomnia.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the regulatory dataset (see Safety Considerations). Diazepam is classically an anxiolytic/sedative-hypnotic, anticonvulsant and skeletal muscle relaxant. |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.9997% (rank 9 of all candidates) |
| Evidence Level | L1 |
| UK Market Status | Not marketed (per current dataset) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the drug-level record (MOA field flagged as a data gap, DG002). However, the prediction’s own rationale supplies the pharmacological link: Diazepam is a positive allosteric modulator of the GABA-A receptor, enhancing inhibitory GABAergic transmission to produce sedative/hypnotic effects. This is a long-established mechanism for benzodiazepines generally, not a novel finding.
This is an important caveat for interpretation: the model’s rationale explicitly notes that diazepam-for-insomnia is not a novel repurposing hypothesis — it reflects pharmacology that has been known for decades (diazepam already has real-world use as a short-term hypnotic). The “new” value of this signal is therefore limited; the KG/GNN model is essentially confirming class-level knowledge rather than surfacing an unexpected therapeutic link.
Consistent with this, the supporting evidence collected is dominated by studies about tapering off benzodiazepine hypnotics (including diazepam) in patients already dependent on them, rather than trials establishing diazepam’s efficacy as a treatment for insomnia. This shifts the practical value of the evidence toward safety/dependence management rather than a new treatment opportunity.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01244711 | Phase 4 | Terminated | 1 | Pilot study substituting quetiapine for chronic benzodiazepine use in treatment-refractory anxiety/depression with insomnia; terminated early with only 1 participant enrolled. |
| NCT04050176 | Phase 3 | Active, not recruiting | 260 | Randomised trial comparing blinded vs. open-label hypnotic tapering combined with CBT-I to improve discontinuation rates of sedative-hypnotics (including benzodiazepines). |
| NCT03687086 | N/A | Completed | 188 | Behavioural-mechanism intervention to help older adults discontinue long-term sleeping pill (hypnotic) use. |
| NCT03405493 | N/A | Completed | 60 | UK community-based sleep therapy/light-box trial for depression; not a diazepam efficacy study. |
| NCT01893632 | Phase 2 | Terminated | 2 | Gabapentin for treatment of benzodiazepine dependence; addresses withdrawal rather than diazepam’s hypnotic efficacy. |
| NCT05935553 | Phase 2/3 | Recruiting | 93 | Baclofen used to assist benzodiazepine dose-tapering in patients with benzodiazepine dependence. |
| NCT04205682 | Early Phase 1 | Unknown | 52 | RCT of cannabidiol for alcohol withdrawal symptoms; diazepam is not the study drug. |
| NCT00678691 | Phase 4 | Completed | 55 | Armodafinil augmentation for fibromyalgia-related fatigue; unrelated to diazepam. |
| NCT05646693 | Phase 2 | Unknown | 58 | Antioxidant therapy combined with Adepsique® (amitriptyline, perphenazine, diazepam) for chronic tinnitus, assessing inflammatory/oxidative markers. |
| NCT03461042 | Phase 4 | Completed | 17 | Placebo-controlled trial of ramelteon combined with benzodiazepine/non-benzodiazepine hypnotics to assist dose reduction in chronic insomnia. |
Note: none of the trials above directly test diazepam’s efficacy as a first-line insomnia treatment; the majority concern discontinuation or dose-reduction of hypnotics in dependent populations.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6113175 | 1981 | RCT | J Int Med Res | Double-blind comparison of lormetazepam vs. diazepam (5 mg) in 100 outpatients with insomnia; lormetazepam showed some superiority in sleep onset/duration, but diazepam was an effective active comparator. |
| 39581171 | 2024 | Review | Bioorganic Chemistry | Reviews small-molecule GABA-A receptor modulators, citing diazepam as a well-known positive allosteric modulator effective for insomnia, anxiety, epilepsy and depression. |
| 36692463 | 2023 | Meta-analysis | Acta Pharmaceutica (Zagreb) | Meta-analysis of tranquilizer use in elderly patients with chronic disease, assessing optimal dosing and adverse effects across benzodiazepine-class agents. |
| 40583063 | 2025 | Clinical/mechanistic | Cell Mol Biol Lett | Reports that long-term use of benzodiazepines (including diazepam) and Z-drugs is associated with exacerbated breast cancer risk, with proposed molecular mechanisms. |
| 29479317 | 2018 | Review | Frontiers in Pharmacology | Reviews Chinese herbal (Suanzaoren) formulae for insomnia, referencing benzodiazepines including diazepam as standard comparators. |
| 40896345 | 2025 | Review | Integrative Medicine Research | Scoping review of herbal medicine/acupuncture for insomnia comorbid with chronic pain, discussing pharmacological hypnotics as current standard treatment. |
| 35228700 | 2022 | Cohort/Preclinical | Nature Neuroscience | Long-term diazepam treatment enhances microglial synaptic pruning and impairs cognitive performance via mitochondrial TSPO, in mice — a mechanistic safety signal for chronic use. |
| 37776625 | 2023 | Preclinical | J Pharm Biomed Anal | Metabolomic study of Naoling Pian for insomnia in a rat model, using diazepam as the positive control comparator. |
| 40350874 | 2025 | Preclinical | China J Chinese Materia Medica | Ziziphi Spinosae Semen extract tested against depression/insomnia-like behaviour in mice, with diazepam (2 mg/kg) as the positive control drug. |
| 23330992 | 2013 | Review | Expert Opin Drug Metab Toxicol | Reviews the pharmacokinetics of anxiolytic drugs, a class that includes diazepam. |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: key warnings, contraindications and drug-interaction data are currently unavailable in this dataset — this is flagged as a Blocking data gap, DG001, that prevents a formal S1 safety pre-screen.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- Diazepam’s GABA-A mechanism plausibly supports a hypnotic effect, and one historical RCT (6113175) directly compares it to another benzodiazepine hypnotic in insomnia patients — but this reflects an already-established, decades-old use rather than a genuinely novel repurposing signal.
- The bulk of the current evidence base concerns tapering/discontinuation of benzodiazepine hypnotics rather than confirming diazepam’s efficacy for insomnia, and long-term-use safety signals (cognitive impairment, cancer association) argue for caution around any new indication for chronic use.
To proceed, the following is needed:
- Resolution of the Blocking data gap (DG001): TFDA/UK product label (SmPC) warnings and contraindications, required before any S1 safety pre-screen can proceed.
- Formal mechanism-of-action documentation (DG002) from DrugBank or equivalent, to support a rigorous mechanistic-link analysis.
- Confirmation of actual UK marketing status and licence details, since the current dataset shows zero licences despite diazepam being a long-marketed medicine — this discrepancy should be verified before any market-status conclusions are drawn.
- If pursued, restriction to short-term/limited use given known dependence, tolerance and cognitive-impairment risks with chronic benzodiazepine use for insomnia.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.